HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance - PubMed
2 days ago
- #regulatory T cells
- #heart transplantation
- #antibody-drug conjugate
- HEV-targeted antibody-drug conjugate (ADC) promotes long-term cardiac allograft acceptance.
- CHST4 plays a critical role in high endothelial venules (HEVs) for naive T cell entry into lymph nodes (LNs), essential for transplant acceptance.
- CHST4 knockout impairs regulatory T cell formation, disrupting heart transplant acceptance under costimulatory blockade.
- A novel ADC targeting CHST4/HEV delivers rapamycin and tubastatin A, enhancing regulatory T cells and suppressing rejection.
- The ADC reduces proinflammatory T cells in LNs and immune cell infiltration in allografts, using lower drug doses.
- CHST4-based ADC therapy shows promise in suppressing heart transplant rejection and improving long-term graft survival.